Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors

A recent subgroup analysis of the TRIBE trial suggested that FOLFOXIRI plus bevacizumab may be a preferred option for the first-line treatment of only right-sided metastatic colorectal cancer (mCRC), regardless of RAS or BRAF status. Our subanalysis of a phase II trial of the FOLFOXIRI triplet regim...

Descripción completa

Detalles Bibliográficos
Autores principales: Sunakawa, Yu, Satake, Hironaga, Ichikawa, Wataru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2018
Materias:
Letter To The Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304303/
https://www.ncbi.nlm.nih.gov/pubmed/30595807
http://dx.doi.org/10.4251/wjgo.v10.i12.528

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304303/
https://www.ncbi.nlm.nih.gov/pubmed/30595807
http://dx.doi.org/10.4251/wjgo.v10.i12.528

Ejemplares similares